The 6-Aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein by Loregian, A et al.
  Published Ahead of Print 1 March 2010. 
10.1128/AAC.01730-09. 
2010, 54(5):1930. DOI:Antimicrob. Agents Chemother. 
Cecchetti and Giorgio Palù
Barbara Gatto, Manlio Palumbo, Oriana Tabarrini, Violetta
Sinigalia, Silvana Pagni, Serena Massari, Giorgio Gribaudo, 
Arianna Loregian, Beatrice Mercorelli, Giulia Muratore, Elisa
 
Immediate-Early 2 Protein
Transactivating Activity of Viral 
Stage by Interfering with the
Cytomegalovirus Replication at an Early 
The 6-Aminoquinolone WC5 Inhibits Human
http://aac.asm.org/content/54/5/1930
Updated information and services can be found at: 
These include:
SUPPLEMENTAL MATERIAL
 Supplemental material
REFERENCES
http://aac.asm.org/content/54/5/1930#ref-list-1at: 
This article cites 38 articles, 21 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 June 19, 2014 by DIP DI SANITA PUBBLICA E M
ICRO
BIO
LO
G
IA
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 June 19, 2014 by DIP DI SANITA PUBBLICA E M
ICRO
BIO
LO
G
IA
http://aac.asm
.org/
D
ow
nloaded from
 
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2010, p. 1930–1940 Vol. 54, No. 5
0066-4804/10/$12.00 doi:10.1128/AAC.01730-09
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
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WC5 is a 6-aminoquinolone that potently inhibits the replication of human cytomegalovirus (HCMV) but
has no activity, or significantly less activity, against other herpesviruses. Here we investigated the nature of its
specific anti-HCMV activity. Structure-activity relationship studies on a small series of analogues showed that
WC5 possesses the most suitable pattern of substitutions around the quinolone scaffold to give potent and
selective anti-HCMV activity. Studies performed to identify the possible target of WC5 indicated that it
prevents viral DNA synthesis but does not significantly affect DNA polymerase activity. In yield reduction
experiments with different multiplicities of infection, the anti-HCMV activity of WC5 appeared to be highly
dependent on the viral inoculum, suggesting that WC5 may act at an initial stage of virus replication.
Consistently, time-of-addition and time-of-removal studies demonstrated that WC5 affects a phase of the
HCMV replicative cycle that precedes viral DNA synthesis. Experiments to monitor the effects of the compound
on virus attachment and entry showed that it does not inhibit either process. Evaluation of viral mRNA and
protein expression revealed that WC5 targets an event of the HCMV replicative cycle that follows the
transcription and translation of immediate-early genes and precedes those of early and late genes. In cell-based
assays to test the effects of WC5 on the transactivating activity of the HCMV immediate-early 2 (IE2) protein,
WC5 markedly interfered with IE2-mediated transactivation of viral early promoters. Finally, WC5 combined
with ganciclovir in checkerboard experiments exhibited highly synergistic activity. These findings suggest that
WC5 deserves further investigation as a candidate anti-HCMV drug with a novel mechanism of action.
Human cytomegalovirus (HCMV) is a ubiquitous herpesvi-
rus that infects the majority of the human population. Al-
though it rarely causes symptomatic disease in healthy, immu-
nocompetent individuals, it is responsible for a variety of
severe diseases in transplant recipients and in human immu-
nodeficiency virus (HIV)-infected patients, including pneumo-
nia, gastrointestinal disease, and retinitis (8, 27). HCMV is also
a major cause of congenital malformations in newborn chil-
dren, often resulting in deafness and mental retardation (8).
Currently, only a few drugs have been approved for the treat-
ment of HCMV infections, i.e., ganciclovir (GCV), foscarnet
(FOS), and cidofovir (CDV), all of which inhibit the viral DNA
(10). GCV, the most widely used anti-HCMV drug, and CDV
are nucleoside analogues that function as DNA chain termi-
nators, whereas FOS inhibits HCMV DNA polymerase
through mimicry of the pyrophosphate product of polymeriza-
tion. These drugs have provided a major advance in anti-
HCMV therapy, but they suffer from poor bioavailability, sig-
nificant toxicity, and limited effectiveness. In addition, the
emergence of drug-resistant viral strains is becoming an in-
creasing problem for disease management, and since the ap-
proved anti-HCMV compounds have similar mechanisms of
action, mutant viruses resistant to one drug are often cross-
resistant to others (41). Thus, although other anti-HCMV
drugs are in clinical development (i.e., maribavir) (1), new
anti-HCMV agents, with good safety profiles and more favor-
able pharmacokinetic properties, that are directed against tar-
gets other than the viral DNA polymerase are still needed.
Recently, we reported the identification of a 6-aminoquin-
olone (6-AQ), WC5, with potent activity against HCMV (25).
Quinolones, whose main structural feature is a 1,4-dihydro-4-
oxo-quinolinyl moiety bearing an essential carboxyl group at
the C-3 position, were first reported as an important class of
broad-spectrum antibacterials able to inhibit prokaryotic type
II topoisomerases (2). Later, several quinolone derivatives
were shown to possess antiviral activity (31); in particular,
some 6-AQs, which are characterized by an amino group at the
C-6 position of the bicyclic quinolone ring system, were shown
to specifically inhibit HIV replication (9, 40). More recently,
some 6-AQs were reported to possess broad-spectrum antiviral
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properties: they were able to inhibit the replication of HCMV
in addition to that of HIV (37). Remarkably, in contrast to
these broad-spectrum 6-AQs, WC5, which is characterized by
a cyclopropyl group at the N-1 position and a 4-(2-pyridyl)-1-
piperazine moiety at the C-7 position (see Table 1), exhibited
specific anti-HCMV activity, in that it did not significantly
affect the replication of other human herpesviruses (i.e., her-
pes simplex virus type 1 and human herpesviruses 6 and 8) and
was 10-fold less active against murine cytomegalovirus (9,
25). In addition, WC5 demonstrated good activity not only
against laboratory strains of HCMV but also against clinical
isolates and virus strains resistant to clinically relevant anti-
HCMV agents (25). These properties prompted us to pursue
our studies on this 6-AQ derivative further.
MATERIALS AND METHODS
Compounds. GCV, FOS, actinomycin D (ActD), and cycloheximide (CHX)
were all purchased from Sigma. The phosphorothioate oligodeoxynucleotides
(ODN) fomivirsen (also known as ISIS 2922) (4) and CpG 2006 (21) were
synthesized by Metabion International AG (Martinsried, Germany). Compounds
WC5, WC5E, WM5, WT5, and WC13 were synthesized as described previously
(9, 40) and were solubilized in 100% dimethyl sulfoxide (DMSO). By following
analogous procedures, the new quinolones WT13 and HC5 were also synthe-
sized; the detailed synthetic procedures are reported in the supplemental mate-
rial.
Cells and virus. Human foreskin fibroblasts (HFF) were maintained in Dul-
becco’s modified Eagle’s medium (DMEM; Life Biotechnologies) supplemented
with 10% fetal bovine serum (FBS; Life Biotechnologies), 100 U/ml penicillin,
and 100 g/ml streptomycin (Life Biotechnologies). HEK (human embryonic
kidney) 293T cells were grown in DMEM supplemented with 10% FBS and
penicillin-streptomycin. The U373-MG UL54-EGFP (clone 2F7) and U373-MG
UL112/113-EGFP (clone 1B4) reporter cell lines (22) were maintained in me-
dium containing 0.75 mg/ml neomycin (G418; Gibco-BRL). HCMV strain AD169
was purchased from the American Type Culture Collection (Manassas, VA).
Antiviral assays. Plaque reduction assays and virus yield reduction assays were
performed as described previously (18).
Cytotoxicity assays. The cytotoxicities of the 6-AQ compounds in HFF were
determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT; Sigma) method as described previously (18).
Proteins. Purified baculovirus-expressed HCMV UL54 and UL44 proteins
were prepared as described previously (19).
DNA polymerase assays. The effects of WC5 and of FOS (used as a control)
on the DNA polymerase activity of HCMV UL54 in vitro, in the absence or
presence of UL44, were tested by a filter-based assay as described previously
(18, 19).
qPCR. To analyze the effect of WC5 on viral DNA synthesis, HFF were seeded
at a density of 1.5  105 per well in 24-well plates. The next day, cells were
infected with HCMV AD169 at a multiplicity of infection (MOI) of 1 or 0.1
PFU/cell and were treated with either 50 M WC5, 10 M GCV, or 0.2%
DMSO as a control. At 72 h postinfection (p.i.), cells were collected, and total
DNA was extracted using the QIAamp DNA extraction kit (Qiagen). The levels
of viral DNA were then determined by quantitative real-time PCR (qPCR) and
were normalized to the cellular -globin gene copies as described previously
(24).
Attachment assays. The effects of WC5 on virus attachment were assessed by
the modification of a procedure previously used to assay herpes simplex virus
type 1 (35). Briefly, 100 PFU of HCMV AD169 and various concentrations of
WC5 or heparin (from porcine intestinal mucosa; Sigma) were added to HFF
monolayers that had been prechilled at 4°C and were incubated for 2 or 4 h at
4°C. Cells were then washed extensively with cold phosphate-buffered saline
(PBS) to remove the compound and unattached virus, overlaid with a compound-
free medium containing 0.6% methylcellulose, and incubated at 37°C for 10 days.
To confirm that incubation at 4°C allowed only viral attachment and not entry,
cells to which the virus had been preattached at 4°C were treated for 1 min with
acidic citrate buffer (40 mM citrate, 10 mM KCl, 135 mM NaCl [pH 3.0]) to
inactivate virus that was attached but had not yet penetrated, and these cells were
then incubated with a medium containing 0.6% methylcellulose at 37°C for 10
days. This reproducibly resulted in 100% inhibition of plaque formation (data
not shown). Cells were then fixed and stained with crystal violet, and plaques
were counted.
Entry assays. One hundred PFU of HCMV AD169 was added to HFF mono-
layers that had been prechilled at 4°C, and the mixture was incubated for 2 h at
4°C to allow viral attachment. Cells were then washed extensively with cold PBS
to remove unattached virus. Various concentrations of WC5 or CpG 2006 as a
control were diluted in serum-free medium and added to the cells, and the
temperature was shifted to 37°C for 2 h. Cells were then treated for 1 min with
citrate buffer (40 mM citrate, 10 mM KCl, 135 mM NaCl [pH 3.0]) to inactivate
the virus that had not entered the cells, washed with PBS three times to restore
a neutral pH, overlaid with a medium containing 0.6% methylcellulose, and
incubated at 37°C for 10 days. Plates were then fixed and stained with crystal
violet, and the plaques were counted. The number of plaques derived from cell
monolayers incubated at 4°C with the virus but not treated with WC5 was taken
as 100%.
Time-of-addition and time-of-removal studies. For time-of-addition studies,
HFF were seeded at 104 per well in 96-well plates, incubated overnight, and
infected the next day with HCMV AD169 at an MOI of 1. After virus adsorption
for 2 h at 37°C, the viral inocula were removed, and the end of viral adsorption
was considered the zero point of the time course. At 0, 1, 2, 6, 9, 12, 24, 32, 48,
56, 60, 72, 78, and 84 h p.i., the cell medium was replaced with a medium
containing 50 M WC5 or 10 M GCV. The plates were incubated at 37°C for
a total of 100 h after infection; at this point, cells were subjected to one cycle of
freezing and thawing, and the amount of viral progeny of each well of the
microtiter plates was determined by titration on fresh HFF cultures.
For time-of-removal studies, HFF were seeded at 104 per well in 96-well
plates, incubated overnight, and infected the next day with HCMV AD169 at an
MOI of 1. Following a 2-h adsorption, cells were incubated with a medium
containing 50 M WC5 or 10 M GCV. At 1, 2, 6, 9, 12, 24, 32, 36, 48, 58, 72,
78, 84, and 96 h following the addition of the drug, the medium was removed and
was replaced with a drug-free medium after three washes. The plates were
incubated for a total of 100 h after infection, and then the virus titer in each
sample was determined as described above.
In both assays, data at each point are expressed as the percentage of the
control data (the virus titer of the no-drug control at the last time point, i.e., 84 h
p.i. for time-of-addition and 96 h p.i. for time-of-removal studies).
RT-PCR assays. HFF were seeded at 6  105 per well in 6-well plates. The
next day, cells were infected with HCMV AD169 at an MOI of 0.1 PFU/cell and
were treated with 50 M WC5 or with 0.2% DMSO as a control. Infected control
samples treated with ActD (5 g/ml), CHX (75 g/ml), or FOS (750 M) as
inhibitors of immediate-early (IE), early (E), and late (L) transcription, respec-
tively, were included. Cells were collected at 16 and 48 h p.i., and total RNA was
extracted using the SV total RNA isolation system (Promega). Then cDNA
synthesis was carried out from 1 g of total RNA using 5 mM MgCl2, 0.25 mM
each deoxynucleoside triphosphate (dNTP), 100 U of RNase inhibitor, 1.25 M
random hexamers, and 150 U of murine leukemia virus (MuLV) reverse trans-
criptase (RT) (all reagents were from Applied Biosystems) in a final volume of
100 l. PCR was then performed using 2 l of cDNA, 1.5 mM MgCl2, 0.2 mM
each dNTP, 20% DMSO, 0.5 M each primer (Invitrogen), and 1.25 U of
AmpliTaq Gold (Applied Biosystems) in a 25-l reaction volume. The following
primers were used: for UL122, 5-ATGTGGATGGCTTGTATTAAG-3 (for-
ward) and 5-CTGGTCAGCCTTGCTTCTAGT-3 (reverse); for UL123, 5-CA
AGAGAAAGATGGACCCTGA-3 (forward) and 5-TCGGCCCCCAGAATG
TAC-3 (reverse); for UL54, 5-CACGATGAATTCATGTTTTTCAACCCG-3
(forward) and 5-CACACGGACCTCGTACACGGG-3 (reverse); for UL84,
5-CACGATGAATTCATGCCACGCGTCGACCCC-3 (forward) and 5-TTC
CACCTGCAGTTAGAGATCGCCGCAGACC-3 (reverse); for UL75, 5-ATA
TGCCTCGATGTCTTTTTG-3 (forward) and 5-CTGGTGATGTCGGTGATC
TGG-3 (reverse); for UL55, 5-TCAGAGTCTTTCAAGTGTCGG-3 (forward)
and 5-ATATGAACGTGAAGGAGTCGC-3 (reverse). Analysis of the cellular
-actin transcript with primers 5-ACGCCTCTGGCCGTACCACTG-3 (forward)
and 5-CTTTTAGGATGGCAAGGGACT-3 (reverse) was included as a control.
PCR amplification was then carried out, and each PCR product was analyzed by
DNA electrophoresis, followed by staining with ethidium bromide.
Western blot analysis. HFF were seeded at 1.5  105/well in 24-well plates.
The next day, cells were infected with HCMV AD169 at an MOI of 0.1 PFU/cell
and were treated with 50 M WC5 or with 0.2% DMSO as a control. Infected
samples treated with either 5 g/ml ActD, 75 g/ml CHX, or 750 M FOS were
included. Cells were collected at 24, 48, and 72 h p.i. and were lysed in 300 mM
NaCl, 500 mM Tris-HCl (pH 8), 0.5% NP-40, and protease inhibitors (Complete
protease inhibitor cocktail tablets; Roche) for 30 min on ice. Proteins were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and were then electroblotted onto a polyvinylidene difluoride (PVDF)
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membrane (Bio-Rad Laboratories). The blots were blocked for 1 h at room
temperature with 5% skim milk in PBS and were then incubated overnight at 4°C
with the following antibody: a mouse monoclonal antibody (MAb) against
HCMV IE1 and IE2 (clone E13; dilution, 1:500; Argene Biosoft), mouse anti-
HCMV UL44 (clone 10-C50; 1:1,000; Fitzgerald Industries International), or
mouse anti-HCMV UL55 (1:1,000; Novus Biologicals). Immunocomplexes were
detected with a goat anti-mouse immunoglobulin antibody (Ab) conjugated to
horseradish peroxidase (diluted 1:2,000; Santa Cruz Biotech) and were visualized
by enhanced chemiluminescence (LiteAblot Extend long-lasting chemilumines-
cent substrate kit; Euroclone). The immunoblots were then stripped and rein-
cubated overnight at 4°C with a mouse anti-human -actin Ab (1:5,000; Sigma).
The immunocomplexes were then detected as described above.
IE2-dependent cell-based assays. For inhibition studies of the IE2 transacti-
vating activity in HCMV-infected cells, the U373-MG UL54-EGFP and
U373-MG UL112/113-EGFP cell lines were seeded onto glass coverslips in
6-well plates at a density of 3  105 cells/well. The next day, monolayers were
infected with HCMV AD169 (MOI, 0.1 or 0.5 PFU/cell) and were then treated
with either 50 M WC5, 5 M fomivirsen, or 0.2% DMSO as a control. The
samples treated with fomivirsen were also pretreated with 5 M fomivirsen for
1 h prior to infection and during infection. At 48 h p.i., the coverslips were fixed
for 15 min with 4% paraformaldehyde in PBS. Following washes with PBS, cells
were mounted using mounting fluid (70% glycerol in PBS) and were imaged
using a Leica TCS-NT/SP2 confocal microscope with a 20 objective. Images
were digitally analyzed with Leica software.
To confirm the inhibition of IE2 transactivating activity, 293T cells at a density
of 4  105/well were seeded onto glass coverslips in 6-well plates and were
incubated overnight at 37°C. The next day, cells were transiently transfected
using the calcium phosphate precipitation method with 1 g of each plasmid.
The pUL54-EGFP, pUL112/113-EGFP, and pSGIE86 plasmids used for trans-
fection have been described previously (22). After incubation for 3 h, the trans-
fection mixtures were removed, and medium containing 50 M WC5, 5 M
fomivirsen, or 0.2% DMSO as a control was added to the cells. At 24 h post-
transfection, cells were fixed and imaged as described above.
Drug combination studies. To evaluate the combined inhibitory effects of
WC5 and GCV on HCMV replication, a checkerboard combination study was
performed using plaque reduction assays. HFF were incubated at 37°C overnight
and were then infected with HCMV AD169. Following a 2-h adsorption, com-
pounds were added to quadruplicate samples. The use of a 6-by-6 grid on a
48-well plate allowed the evaluation of WC5 at concentrations of 0, 0.05, 0.1, 0.5,
1, and 2 M in combination with GCV at 0, 0.1, 0.5, 1, 2, and 4 M. After a
10-day incubation, cells were fixed and stained with crystal violet, and plaques
were counted. The data were analyzed by the isobologram method according to
the methods of references 12 and 36. In this analysis, the 50% effective concen-
trations (EC50s) were used for the calculation of the fractional inhibitory con-
centration (FIC) as follows: FICx  (EC50 of compound X in combination)/
(EC50 of compound X alone); FICy  (EC50 of compound Y in combination)/
(EC50 of compound Y alone). When the FIC index, which corresponds to the
sum of the FIC values of the combined compounds (FIC index  FICx  FICy),
is equal to 1, the combination is additive; when the FIC index is between 1.0 and
0.5, the combination is partially synergistic; when it is 0.5, the combination is
synergistic; when it is between 1.0 and 2.0, the combination is partially antago-
nistic; and finally, when it is 	2.0, the combination is antagonistic.
RESULTS
SAR studies of WC5. In a previous report (25), we compared
the anti-HCMV activity and cytotoxicity of WC5 with those of
two 6-AQ analogues, WM5 and WT5, which maintain 4-(2-
pyridinyl)piperazine at the C-7 position but bear a methyl and
a tert-butyl moiety, respectively, instead of the cyclopropyl
group at the N-1 position (Table 1). Among these compounds,
WC5 exhibited the highest selectivity index, having potent an-
tiviral activity coupled with low cytotoxicity (Table 1) (25). This
observation highlighted the key role of the N-1 substituent in
modulating compound potency and selectivity. In order to ac-
quire further structure-activity relationship (SAR) informa-
tion, and in an attempt to increase the potency of WC5, some
structural modifications were planned. In particular, com-
pound HC5 was synthesized, in which the amino group at C-6
was replaced by a hydrogen atom. The 6-hydrogen derivative
maintained low cytotoxicity but exhibited a 6-fold decrease in
antiviral activity (Table 1), indicating that the amino group in
the C-6 position is important for preserving potent anti-
HCMV activity. This is in agreement with recent reports on
other 6-hydrogen-1-methylquinolones, which were found to be
inactive against HCMV (39). To explore the importance of the
carboxylic substituent at the C-3 position, the anti-HCMV ac-
tivity of WC5E, the ethyl ester analogue of the lead compound,
WC5 (9), was also tested. This compound was completely de-
void of anti-HCMV activity (Table 1), suggesting that the
3-carboxylic function likely plays a major role in the recogni-
tion of the target involved in the mechanism of antiviral activ-
ity. Then we turned our attention to the C-7 position of the
quinolone nucleus. It was previously reported that the 6-AQ
derivative WC13, characterized by a benzothiazolpiperazinyl
moiety at the C-7 position, exhibited potent anti-HCMV ac-
tivity (25, 37). However, this compound also had high cytotox-
icity, likely due to broad-spectrum transactivation-interfering
properties (25, 37). In an attempt to preserve the potency of
WC13 while decreasing its cytotoxicity, we planned the synthe-
sis of WT13, in which the N-1 tert-butyl group, which would
confer low toxicity (25), was coupled with the C-7 benzothia-
zolpiperazinyl moiety, which would impart high antiviral activ-
ity. Compound WT13 maintained good anti-HCMV activity,
confirming the suitability of the benzothiazolpiperaziny moi-
ety, but unfortunately, this was coupled with high cytotoxicity,
a pattern analogous to that shown by the N-1 cyclopropyl
derivative WC13 (Table 1).
Taken together, the SAR information derived from the
small series of analogues synthesized showed that WC5 pos-
sesses the most suitable pattern of substitutions around the
quinolone scaffold for conferring potent and selective anti-
HCMV activity. Thus, subsequent studies were focused on the
further characterization of WC5 activity.
The anti-HCMV activity of WC5 does not rely on inhibition
of viral DNA polymerase. We previously showed that WC5
retains its activity against HCMV strains resistant to DNA
polymerase inhibitors (GCV, CDV, acyclovir [ACV], and
FOS) (25), which suggested that the antiviral activity of WC5
does not likely entail inhibition of viral DNA polymerase.
However, it has been reported that some compounds structur-
ally related to 6-AQ, i.e., 4-oxo-dihydroquinoline carboxam-
ides, which are active against both GCV-resistant and CDV-
resistant HCMV strains, also show activity against HCMV
DNA polymerase (7, 28). Thus, to investigate whether WC5
might inhibit the HCMV DNA polymerase through a mecha-
nism different from that of GCV, CDV, ACV, and FOS, we
tested the effects of the compound on the activity of the viral
enzyme in vitro. The enzyme activity in the presence of serial
dilutions of WC5 or of FOS as a control was evaluated by
measuring the incorporation of [3H]dTTP into a poly(dA)-
oligo(dT)12–18 template-primer by a purified, baculovirus-ex-
pressed DNA polymerase catalytic subunit (UL54) both in the
absence and in the presence of the accessory subunit (UL44).
As expected, FOS inhibited the DNA polymerase activities of
both UL54 alone and the UL54/UL44 complex in a dose-
dependent manner, with 50% inhibitory concentrations (IC50s)
of 3.1 M and 5.5 M, respectively (Fig. 1). In contrast, WC5
showed very weak inhibitory activity against both UL54 alone
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and the UL54/UL44 complex (Fig. 1), exhibiting IC50s (	100
M) much higher than the EC50 observed in plaque reduction
assays in HCMV-infected cells (0.9 M) (Table 1) (25). Thus,
it seems unlikely that the anti-HCMV properties of this 6-AQ
derivative are due to inhibition of the polymerization activity
of the viral DNA polymerase.
Effects of WC5 on viral DNA synthesis. Given the ability of
quinolones to interact with protein-nucleic acid complexes (2,
30), the possibility existed that WC5 might inhibit HCMV
DNA replication either by affecting the activity of a component
of the DNA replication complex other than the viral polymer-
ase or of a protein(s) indirectly involved in virus genome rep-
lication (26, 29) or by interfering with DNA maturation. To
test this hypothesis, the effect of WC5 on viral DNA synthesis
in HCMV-infected cells was quantitatively determined by
qPCR at 72 h p.i. (Fig. 2). GCV was used as a control, and as
expected from its mode of action, it strongly inhibited HCMV
DNA replication. Similarly, 98% inhibition of viral DNA syn-
thesis was observed in the presence of WC5. Thus, WC5 ap-
pears to prevent viral DNA synthesis, suggesting that it likely
interferes with an event of the HCMV replication cycle that
precedes or takes place during virus DNA replication.
The antiviral activity of WC5 depends on the MOI. To
characterize further the antiviral activity of WC5, we per-
formed yield reduction experiments in HFF infected with
HCMV at an MOI of 1 PFU/cell. Interestingly, in these assays
WC5 showed an activity almost 10-fold lower (EC50, 8.6 
 2.1
M) than that exhibited in plaque reduction assays (EC50,
0.9
 0.2 M) (Table 1) (25). One possible explanation was the
different MOIs used in the two assays. To examine the effects
of MOI on the anti-HCMV activity of WC5, yield reduction
assays were performed at three different MOIs (0.01, 0.1, and
1 PFU/cell). Dose-response curves for WC5 at the three MOIs
tested were very different, with significantly lower antiviral
activity observed at an MOI of 1 PFU/cell than at an MOI of
0.01 PFU/cell (see Fig. S1 in the supplemental material). To
TABLE 1. Chemical structures, antiviral activities against HCMV, and cytotoxicities of quinolone derivatives
Compound
Chemical compositiona Antiviral
activityb Cytotoxicity
c SId
R1 R3 R6 R7
WC5e c-Pr OH NH2 0.9 
 0.2 431 
 61 479
WM5e Me OH NH2 0.7 
 0.2 54 
 15 77
WT5e t-But OH NH2 36.7 
 15.2 475 13
HC5 c-Pr OH H 5.6 
 1.3 390 
 37 70
WC5E c-Pr O-Et NH2 	50 409 
 46 	8
WC13e c-Pr OH NH2 0.02 
 0.05 4.5 
 3.9
225
WT13 t-But OH NH2 0.18 
 0.1 5.8 
 2.3 32
GCVe 1.9 
 0.2 550 
 75 289
a Me, methyl; c-Pr, cyclopropyl; t-But, tert-butyl; Et, ethyl.
b Expressed as the EC50 (in micromolar concentrations), defined as the concentration of the compound that inhibits 50% of plaque formation, as determined by
plaque reduction assays against HCMV AD169 in HFF. Reported values are means 
 standard deviations of data derived from at least three independent experiments
performed in duplicate.
c Expressed as the CC50 (in micromolar concentrations), defined as the concentration of the compound that produces 50% cytotoxicity as determined by MTT assays
in HFF. Reported values are means 
 standard deviations of data derived from at least three independent experiments performed in quadruplicate.
d SI, selectivity index, determined as the ratio between the CC50 and the EC50.
e Data for this compound were reported in reference 25.
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explore this MOI dependency further, we compared the effects
of MOI on the antiviral activity of WC5 with those on GCV
activity. In repeated experiments, there was no statistically
significant difference among the EC90s of GCV at three dif-
ferent MOIs (Table 2), as determined by paired t tests
(P, 0.05). This result is in agreement with previous observa-
tions that GCV does not act in an MOI-dependent manner
(17, 36). In contrast, there were significant differences among
the EC90s of WC5 at all MOIs tested (Table 2), with the
greatest difference between the EC90s of WC5 at MOIs of 1
and 0.01 PFU/cell (P, 0.005), as expected. These data indicate
that the antiviral activity of WC5, unlike that of GCV, is highly
dependent on the viral inoculum, as shown for other early-
acting antiherpetic compounds whose antiviral activity was
MOI dependent (6, 13, 15). Thus, this finding suggests that
WC5 might act early in the virus replication cycle.
WC5 does not affect the attachment and entry of HCMV. We
therefore investigated whether WC5 might affect the initial
phases of the virus life cycle, i.e., attachment and/or entry. To
examine the effects of WC5 on the viral adsorption stage, we
tested the inhibition of plaque formation when WC5 was
present for 2 or 4 h only during viral attachment at 4°C (a
condition that is known to allow virus adsorption only). As a
positive control, we assayed the susceptibility of viral attach-
ment to heparin, which is a polyanionic molecule chemically
similar to heparan sulfate moieties located on the cell surface
and has been shown to inhibit the attachment of HCMV (16).
As expected, heparin was able to inhibit virus attachment po-
tently (EC50, 0.15 M [Fig. 3A]). In contrast, WC5 did not
significantly reduce the binding of HCMV virions to HFF.
To test the effects of WC5 on viral entry, we preattached the
virus to cells at 4°C in the absence of drug, added various
concentrations of WC5, and then incubated the mixtures at
37°C for 2 h to permit entry. The ODN CpG 2006, which has
been shown to block HCMV entry (21), was included as a
control. After virus that had not entered was inactivated with
acidic citrate buffer, plaques were allowed to form and were
then counted. As shown in Fig. 3B, WC5 did not significantly
affect the entry of HCMV (EC50, 	25 M), while CpG 2006
exhibited inhibitory activity. Thus, these results indicate that
WC5 does not block either the adsorption of the virion particle
to the host cell or virus entry.
Time-of-addition and time-of-removal studies. To deter-
mine the phase of the HCMV replication cycle that is affected
by WC5, experiments were performed in which 50 M WC5,
or 10 M GCV for purposes of comparison, was added to
infected cells at different times p.i., and the HCMV titer was
determined at 100 h p.i. Such compound concentrations were
selected because they were able to completely inhibit HCMV
replication in HFF but were not cytotoxic (25). Viral replica-
tion was fully blocked when WC5 was added up to 30 h p.i.
(Fig. 4A). Increasing viral titers were observed when WC5 was
added from 30 h to 84 h p.i. GCV, on the other hand,
markedly reduced virus yield when it was added up to 56 to
60 h p.i., when HCMV DNA replication occurs (38), but it
produced lower or no reductions in viral titers when added at
72 h p.i. or later (Fig. 4A). These results suggest that WC5
likely targets a process occurring earlier than DNA synthesis.
Studies to examine the effect of removal of WC5 at various
FIG. 1. WC5 does not significantly inhibit the activity of HCMV
DNA polymerase in vitro. The effects of increasing concentrations of
WC5 (filled symbols), and of FOS as a control (open symbols), on the
activity of the purified, baculovirus-expressed HCMV DNA polymer-
ase catalytic subunit UL54 in the absence (circles) and in the presence
(squares) of the accessory subunit UL44 were determined by filter-
based DNA polymerase assays. The data shown are means 
 standard
deviations (error bars) for four independent experiments.
FIG. 2. WC5 prevents viral DNA synthesis in HCMV-infected
cells. HFF were either infected with HCMV AD169 (MOI, 0.1) or
mock infected (Mock) and were then treated with either WC5, GCV,
or DMSO as a control. At 72 h p.i., total DNA was extracted, and
qPCR was performed with appropriate IE2 and -actin primers.
HCMV genomic copies were normalized to the cellular -actin gene
copies. Data shown are means 
 standard deviations (error bars) for
three independent experiments performed in duplicate.
TABLE 2. Effects of MOI on antiviral activities of WC5 and GCV
MOI
(PFU/cell)
EC90 (M)a
WC5 GCV
1 51.9 
 11.4 0.8 
 0.3
0.1 34.7 
 9.4 1.0 
 0.1
0.01 8.5 
 1.7 1.0 
 0.2
a Defined as the concentration of the compound that inhibits 90% of infectious
virus yield as determined by yield reduction assays in HFF infected with HCMV
AD169 at different MOIs. Reported values are means 
 standard deviations of
data derived from at least three independent experiments performed in dupli-
cate.
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times p.i. were performed to further elucidate when the 6-AQ
derivative acts in the virus lytic cycle. HFF monolayers were
infected with HCMV AD169 and were treated with 50 M
WC5 or 10 M GCV. The compounds were then washed from
the cultures at various times p.i. up to 96 h, and the amount of
infectious virus released was determined at 100 h p.i. As shown
in Fig. 4B, removal of GCV prior to viral DNA synthesis
resulted in a partial block of HCMV replication, with complete
inhibition observed from 48 h p.i. In contrast, WC5 appeared
to possess diminished activity if it was removed as early as 12 h
p.i., and it completely blocked HCMV replication from 36 h
p.i. These observations are consistent with the results of the
time-of-addition studies, which showed that WC5 acts before
GCV in the HCMV lytic cycle.
Effects of WC5 on HCMV gene transcription and protein
expression. To gain deeper insight into the mechanism of WC5
antiviral activity, its effects on the transcription of selected viral
immediate-early (IE), early (E), and late (L) genes were stud-
ied using RT-PCR analysis. Transcripts were selected as rep-
resentatives of their kinetic class, irrespective of any specific
role in HCMV replication. HFF were infected with HCMV
and were treated with 50 M WC5. The RNA synthesis inhib-
itor ActD, the protein synthesis inhibitor CHX, and the viral
DNA polymerase inhibitor FOS were included in order to
temporally categorize each transcript. RNA extracts were pre-
pared at 16 and 48 h p.i. (within the first viral replication cycle),
and RT-PCR amplification of HCMV transcripts and human
-actin mRNA was performed on the same cDNA sample. The
FIG. 3. WC5 does not interfere with the adsorption and entry of HCMV. (A) Effects on attachment. HCMV AD169 was allowed to attach to
HFF at 4°C in the presence of various concentrations of WC5 (f) or heparin (F) as a control. (B) Effects on entry. HCMV AD169 was attached
to cells at 4°C; unattached virus was removed; and the cells were incubated for 2 h at 37°C in the presence of various concentrations of WC5 (f)
or ODN CpG 2006 (F) as a control. The data shown in both panels are means
 standard deviations for three experiments carried out in duplicate.
FIG. 4. Effects of addition and removal of WC5 at different time-points after HCMV infection. (A) Effects of time of addition of WC5 and
GCV on HCMV yield. HFF were infected with HCMV AD169 at an MOI of 1 and were then treated with WC5 (f) or GCV (F at 0, 1, 2, 6, 9,
12, 24, 32, 48, 56, 60, 72, 78, or 84 h p.i. The antiviral activity of each compound is expressed as a percentage of the virus titer in the untreated
infected samples. (B) Effects of time of removal of WC5 or GCV on HCMV yield. HFF were infected with HCMV AD169 at an MOI of 1 and
were treated with WC5 (f) or GCV (F). At 1, 2, 6, 9, 12, 24, 32, 36, 48, 58, 72, 78, 84, or 96 h p.i., the cells were rinsed to remove the compound,
and fresh medium was added; infected cultures with no compound were treated identically to serve as controls. In both panels, the data shown are
means 
 standard deviations for three experiments carried out in duplicate.
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time points chosen for RNA extraction exceed those generally
used for studying superinduction of HCMV IE mRNA (see,
e.g., reference 14); however, the 16- and 48-h time points
enabled us to detect at the same time IE/E and E/L gene
expression, respectively, as already reported in studies of other
anti-betaherpesvirus compounds (see, e.g., references 11 and
28). Based on their decreased levels following incubation with
ActD, CHX, or FOS, the selected HCMV transcripts were
categorized as IE (UL122 and UL123), E (UL54 and UL84),
or L (UL55 and UL75). No IE, E, or L mRNAs were present
in the ActD-treated samples, as expected, while WC5 had no
inhibitory effect on the transcription of the IE genes UL122
and UL123 (Fig. 5). In contrast, the levels of the two early
transcripts, UL54 and UL84, were clearly reduced following
incubation with WC5 as well as with CHX, while no significant
effect of FOS was observed on the transcription of these genes.
Both WC5 and FOS strongly inhibited the expression of the
UL55 and UL75 late genes.
We next examined the effects of WC5 on overall HCMV
protein synthesis. For this purpose, HFF were infected with
HCMV and were then incubated with WC5 or 0.2% DMSO as
a control, and the expression of viral IE, E, and L proteins was
evaluated by both Western blotting and immunofluorescence
at various times p.i. Infected control samples treated with
ActD, CHX, or FOS as inhibitors of IE, E, and L gene expres-
sion, respectively, were included. Western blot analysis after
24 h (Fig. 6, left) showed strong expression of the IE proteins
p72 and p86, which was completely inhibited by CHX, whereas
WC5 had no influence on the expression of these proteins. At
48 h p.i., the expression of the early protein UL44 was not
completely inhibited but was strongly reduced by WC5 (Fig. 6,
center). The HCMV late protein UL55 was not detected in the
presence of WC5 or of FOS at 72 h p.i. (Fig. 6, right). Similar
effects were observed when cells were stained with antibodies
against the same IE (p72/p86), E (UL44), and L (UL55) pro-
teins (data not shown).
Taken together, these results demonstrate that WC5 targets
an early phase of the viral replicative cycle that follows the
transcription and translation of IE genes and precedes those of
E and L genes.
Effects of WC5 on HCMV IE2 transactivating activity. The
results presented above suggested that WC5 might act by in-
hibiting the activity of IE proteins. HCMV IE genes encode
the transcriptional regulators IE1 (p72) and IE2 (p86), which
are required for the subsequent expression of E and L genes
(23). In particular, the IE2 protein has been shown to play a
crucial role in the transactivation of viral E and L genes (23).
To analyze the effects of WC5 on IE2-mediated E gene trans-
activation in HCMV-infected cells, we employed a cell-based
assay (22) in which the expression of the enhanced green
fluorescent protein (EGFP) reporter gene is driven by the
UL54 or UL112/UL113 E gene promoter, both of which are
transactivated by IE2 protein during HCMV replication (3, 34,
42). U373-MG cells stably transfected with a plasmid express-
ing the UL54-EGFP or UL112/113-EGFP reporter were in-
fected with HCMV at an MOI of 0.1 or 0.5 and were subse-
quently treated with WC5 or with fomivirsen (ISIS 2922) as a
reference compound. Analysis of EGFP expression in control
HCMV-infected cells (MOI, 0.1) at 48 h p.i. showed a specific
fluorescence signal (Fig. 7A). As expected, the HCMV-in-
duced EGFP expression was almost completely prevented by
treatment of indicator cells with fomivirsen, an antisense oli-
godeoxynucleotide designed to block IE2 expression (4). A
pronounced inhibitory effect was also observed when infected
cells were treated with WC5 (Fig. 7A). Similar effects were
detected in cell monolayers infected with HCMV at an MOI of
0.5 (data not shown).
To confirm that the effects observed in HCMV-infected cells
could be ascribed to inhibition of IE2 transactivating activity,
293T cells were transiently cotransfected with the UL54-EGFP
or UL112/113-EGFP reporter plasmid and with an expression
vector for IE2 (pSGIE86); then they were treated with either
FIG. 5. WC5 inhibits transcription from viral E and L genes but not
from viral IE genes. HFF were either infected with HCMV AD169
(MOI, 0.1) or mock infected and were treated with WC5 or DMSO as
a control. Infected cell samples treated with ActD, CHX, and FOS
were included as controls for inhibition of IE, E, and L gene expres-
sion, respectively. At 16 and 48 h p.i., total RNA was extracted and
reverse transcribed. PCRs were then carried out with primers for the
UL122 and UL123 (IE), UL54 and UL84 (E), and UL55 and UL75
(L) genes. Human -actin was included as a control. PCR products
were analyzed in ethidium bromide-stained agarose gels.
FIG. 6. Effects of WC5 on the expression of HCMV IE, E, and L
proteins. HFF were either infected with HCMV AD169 (MOI, 0.1) or
mock infected and were then treated with WC5 or with DMSO as a
control. At 24, 48, and 72 h p.i., whole-cell extracts were prepared,
fractionated by SDS-PAGE, and analyzed by Western blotting (WB)
with anti-IEA (IE1 and IE2), anti-UL44, and anti-UL55 antibodies.
Controls for inhibition of gene expression were ActD (24 h), CHX (48
h), and FOS (72 h). Immunodetection of cellular -actin was also
included as an internal control.
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WC5, fomivirsen, or 0.2% DMSO as a control. A significant
increase in EGFP expression was observed in DMSO-treated
cells (Fig. 7B). Treatment with fomivirsen reduced the IE2-
induced EGFP fluorescence to background levels in both
UL54-EGFP- and UL112/113-EGFP-expressing cells (Fig.
7B). Consistent with the results from assays in HCMV-infected
cells, WC5 also markedly reduced EGFP expression (Fig. 7B).
When different concentrations of WC5 were tested, an EC50 of
8 M for inhibition of IE2 transactivation was determined
(B. Mercorelli and A. Loregian, unpublished results).
Taken together, these results strongly suggest that WC5 inter-
feres with the IE2-mediated transactivation of E gene promoters.
Drug combination studies. Since WC5 appeared not to
share the same target as GCV, we then wanted to investigate
whether a combination of the two compounds would result in
synergistic activity against HCMV replication. The combined
effects of WC5 and GCV on the replication of HCMV AD169
in HFF were evaluated by plaque reduction assays and were
then analyzed by an isobologram method (12). Figure 8 is an
isobologram representing the WC5-GCV interaction; in this
figure, the solid line represents the theoretical plot for an
additive interaction between the two compounds (which is the
expression of an independent antiviral effect), while the broken
line represents the theoretical plot for a significant synergistic
interaction. Since the FIC values obtained for several of the
combinations of WC5 and GCV were located under the plot
representing synergism (FIC index, 0.5), we concluded that
the two compounds interact in a strongly synergistic manner,
each reinforcing the other’s anti-HCMV activity. Importantly,
WC5, when combined with GCV and tested for its 50% cyto-
toxic concentration (CC50) toward growing HFF, proved addi-
tive rather than synergistic (data not shown), suggesting that
the highly synergistic antiviral activity was not due to an in-
creased CC50 but, plausibly, the result of interference with two
different steps of the viral replicative cycle.
DISCUSSION
WC5 has recently emerged, among a series of 6-AQ deriv-
atives tested for their anti-HCMV activities, as an antiviral
FIG. 7. WC5 inhibits the transactivation of E promoters by IE2. (A) U373-MG cells stably transfected with the pUL54-EGFP or the
pUL112/113-EGFP plasmid were either infected with HCMV AD169 (MOI, 0.1) or mock infected. Cells were then treated with either WC5,
fomivirsen, or DMSO as a control. At 48 h p.i., the cells were examined by confocal fluorescence microscopy to evaluate the number of
EGFP-expressing cells. (B) 293T cells either were transiently transfected with the UL54-EGFP or the UL112/113-EGFP reporter plasmid alone
or in combination with pSGIE86 or were mock transfected (Mock). Cells were then treated with WC5, fomivirsen, or DMSO as a control. At 24 h
after transfection, the cells were analyzed for EGFP expression by confocal fluorescence microscopy. Representative images are shown for both
panels.
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agent with an in vitro activity equal to or greater than that of
GCV against both laboratory strains and clinical isolates of
HCMV (25). Intriguingly, a striking feature of WC5 is its
specificity for HCMV, as it has essentially no or little inhibitory
activity against other human or animal herpesviruses (25). In
stark contrast, other 6-AQs have been reported to possess
broad-spectrum antiviral properties, as they can inhibit HIV
and murine CMV in addition to HCMV replication (37). Since
the specific antiviral activity of WC5 might provide an inter-
esting platform for future clinical applications, in the present
study the nature of the anti-HCMV activity of this compound
has been further examined.
Our previous observation that HCMV strains showing resis-
tance to GCV, ACV, CDV, or FOS are still sensitive to WC5
(25) suggested that the HCMV DNA polymerase could not
serve as a target for this 6-AQ derivative. Indeed, when WC5
was examined for its effects against the HCMV DNA polymer-
ase catalytic subunit, UL54, in in vitro DNA polymerase assays,
no significant inhibitory activity was observed (Fig. 2). There-
fore, it was concluded that most likely WC5 does not directly
target UL54 activity. However, it should be kept in mind that
HCMV DNA synthesis in infected cells requires the interac-
tion of UL54 with the DNA polymerase accessory protein
UL44, which binds double-stranded DNA (dsDNA) with high
affinity and stimulates UL54-mediated DNA polymerase activ-
ity (19, 20). Thus, by including this protein in the reaction
mixture of the DNA polymerase assays, we also investigated
whether WC5 might indirectly inhibit HCMV DNA polymer-
ase by interfering with the activities of UL44, e.g., through
disruption of its interaction with UL54, as reported for other
compounds (18), or through inhibition of its DNA-binding
activity. Our data indicate that most likely the DNA polymerase
accessory protein can also be excluded as a potential target for
WC5. Of note, in contrast to WC5, structurally related 4-oxo-
dihydroquinoline carboxamides were highly active against the
HCMV DNA polymerase and exhibited broad-spectrum antiher-
pesvirus activity (7, 28).
Experiments to test the effects of WC5 on HCMV DNA
replication showed that it prevents viral DNA synthesis, sug-
gesting that it might act by inhibiting a protein(s), other than
the viral DNA polymerase, directly or indirectly involved in
virus genome replication (26, 29). However, time-of-addition
and time-of-removal studies then revealed that WC5 targets an
early event in the HCMV replicative cycle that takes place
prior to viral DNA replication. In fact, compared to the refer-
ence compound GCV, which targets the viral DNA polymer-
ase, WC5 was able to inhibit HCMV replication when added
earlier in infection than the DNA synthesis inhibitor. In addi-
tion, the inhibition was not reversible, suggesting either tight-
binding inhibition of a viral target or inhibition of an early viral
event required for subsequent replication steps. Among the
first events that take place during the virus replication cycle, a
block of viral adsorption or penetration could be excluded
based on our results that no significant inhibition of HCMV
infection was observed when WC5 was present only during the
attachment or entry phase.
In a pattern typical of herpesviruses, HCMV gene expres-
sion is temporally regulated after infection and can be divided
into immediate-early (IE), early (E), and late (L) phases (27).
Therefore, we next analyzed both viral gene transcription and
protein expression throughout the virus replicative cycle in
WC5-treated cells. Our results clearly pointed to a step of the
virus replicative cycle that follows the expression of IE antigens
and precedes that of E and L antigens as the target for WC5.
Since it has been shown that the IE2 protein plays a major role
in regulating the expression of viral E and L genes (23), we
hypothesized that WC5 might interfere with the IE2 transac-
tivating activity. We show here that WC5 does inhibit IE2-
mediated transactivation of two different HCMV E promoters.
Importantly, we previously reported that WC5 did not affect
GFP expression driven by cellular and other viral promoters
(25). Of note, consistent with the results of the studies on the
effects of WC5 on HCMV gene transcription and expression
(Fig. 6 and 7), WC5 also did not interfere with the transacti-
vation of the HCMV IE promoter (25). Thus, the inhibition of
IE2 transactivating activity does not stem from broad-spectrum
transactivation-interfering properties such as those possessed
by other 6-AQs (37). Further exploratory work, such as the
isolation and characterization of WC5-resistant viruses, will be
required in order to provide a better understanding of the
molecular basis of the anti-IE2 activity of WC5 and to dem-
onstrate the link with its highly specific anti-HCMV activity.
However, as reported in earlier studies with compounds that
inhibit HCMV at an early step in replication (see, e.g., refer-
ences 6 and 36), the isolation of drug-resistant mutants might
not be feasible. Indeed, after 6 months of passage in cell
culture according to the procedure described by Biron et al. (5)
no virus resistance against WC5 has been detected yet (B.
Mercorelli and A. Loregian, unpublished results).
Whatever the molecular mechanism may be, the inhibition
of IE2 activity could prove to be beneficial at more than one
FIG. 8. Effects of combinations of WC5 and GCV on HCMV rep-
lication. HFF were infected with HCMV AD169 and were then treated
with different concentrations of WC5 either alone or combined with
different concentrations of GCV. The data for each compound are
reported as the fractional inhibitory concentration (FIC), calculated by
dividing the EC50 of compound X in combination with compound Y by
the EC50 of compound X alone. The solid and broken lines represent
the unit lines for FICs equal to 1 and 0.5, respectively. The FIC index,
which is the FIC of compounds X and Y combined, is given for every
combination of concentrations. A FIC index between 0.5 and 0.9 is
suggestive of partial synergism, whereas a FIC index of 0.5 indicates
significant synergism. The results are from a single experiment per-
formed in quadruplicate, representative of two independent experi-
ments.
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level. There is compelling evidence that IE2 plays a direct role
in the pathogenesis of HCMV infection by inducing a broad
dysregulation of host gene expression. This leads to changes in
host cell physiology and contributes to HCMV-induced cell
cycle alterations, immunomodulation, and proinflammatory
responses (32). Thus, molecules that reduce IE2 expression
(such as fomivirsen) or inhibit IE2-dependent activities may be
effective in blocking the virus-induced pathological phenom-
ena at an early stage of infection. Moreover, inhibitors of IE2
could be of particular importance for the treatment of patients
who do not respond to the currently used inhibitors of viral
DNA replication (33). Although a number of compounds with
anti-HCMV activity have been reported to act at early stages
of virus replication, their targets are still mostly unknown, and
fomivirsen, the sole approved anti-HCMV drug specifically
designed against IE2, is no longer marketed.
In addition, since WC5 and GCV act against different viral
targets, the use of these two compounds in combination could
potentiate the effect of each compound alone. Indeed, our
drug combination studies showed that when WC5 and GCV
are used in combination, inhibition of viral replication is
achieved at lower drug concentrations than when the drugs are
used individually (Fig. 8). Thus, WC5 and GCV exhibit strong
synergistic antiviral activity without significantly increased tox-
icity. Combination therapy with a reduced GCV dose may
result in similar synergistic effects, providing a means to treat
HCMV infectious diseases while reducing drug toxicity and the
emergence of drug-resistant mutants.
In summary, this is the first study—to our knowledge—
showing that a potent anti-HCMV compound acts by inhibiting
the IE2 transactivating activity; thus, this compound has a
target clearly different from that of the anti-HCMV drugs
currently approved for clinical use. This observation, together
with our previous finding that WC5 is not cross-resistant with
ganciclovir, acyclovir, cidofovir, and foscarnet (25), may offer
an important advantage in the potential clinical use of this
compound, since drug-resistant HCMV strains often emerge
after long-term treatment with antiherpetic drugs. Further-
more, the observation that WC5 shows synergism upon co-
treatment with ganciclovir opens up the possibility for drug
combinations, although this is not common practice in herpes-
virus therapy. Thus, WC5 deserves further investigation as a
candidate anti-HCMV drug.
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